aTyr Pharma
ATYR
15 hedge funds and large institutions have $8.02M invested in aTyr Pharma in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
321% more capital inflows, than outflows
Capital inflows: $541K | Capital outflows: $129K
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
1.7% more ownership
Funds ownership: 47.76% → 49.46% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
17% less funds holding
Funds holding: 18 → 15 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$174K |
| 2 |
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$87.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$53.1K |
| 4 |
Virtu Financial
New York
|
+$43.3K |
| 5 |
Renaissance Technologies
New York
|
+$24.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$107K |
| 2 |
Tower Research Capital (TRC)
New York
|
-$16.2K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.4K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$2K |
ATYR Hedge Fund Activity: Q4 2019 in Review
15 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q4 2019, worth a combined $8.02M — up 23% from $6.5M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ATYR positions and 3 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Federated Hermes, adding an estimated $174K. The largest seller was Acadian Asset Management, exiting entirely with an estimated $107K sold.
- 15 institutional investors held aTyr Pharma (ATYR) as of Q4 2019, down from 18 in Q3 2019.
- Funds reported $8.02M of aTyr Pharma stock for Q4 2019, up 23% quarter-over-quarter.
- 5 funds opened new aTyr Pharma positions in Q4 2019 and 3 closed out, a net change of +2 holders.
- The largest aTyr Pharma buyer in Q4 2019 was Federated Hermes, an estimated $174K added.
- The largest aTyr Pharma seller in Q4 2019 was Acadian Asset Management, an estimated $107K sold.
Based on aggregated 13F filings for Q4 2019.